Composition of DC vaccine and NKG2A antagonist and application of composition in anti-breast cancer or liver cancer

Abstract

The invention provides a composition of a DC vaccine and an NKG2A antagonist and application of the composition in anti-breast cancer or liver cancer. The DC vaccine in the composition is different from the early traditional tumor cell full-antigen-loaded DC vaccine, has specific targeting antigens, can more accurately treat tumors and reduce the killing side effects on normal cells; and secondly,the composition further contains a novel immune checkpoint inhibitor NKG2A antagonist which enables tumor cells with CD94-NKG2A / HLA-Ereceptor-ligand on the surface to be recognized and killed by NK cells and T cells, and an antigen presentation function of dendritic cells is enhanced, so that some cells which are not subjected to presentation and antigen by the DC vaccine are captured by an immune system again, the treatment effect on breast and liver cancer is enhanced, effect is faster than the conventional DC vaccine, the time of duration is longer, and the immunotherapy process is promoted.

Description

technical field [0001] The invention relates to the technical field of biological immunity, in particular to a composition of DC vaccine and NKG2A antagonist and its application in fighting breast cancer or liver cancer. Background technique [0002] Breast cancer is a malignant tumor that occurs in the glandular epithelial tissue of the breast, 99% of which occur in women. The number of new breast cancer cases worldwide ranks first among female malignant tumors every year. In recent years, the incidence of breast cancer in China has also increased year by year. In 2017, it was as high as 43 / 100,000. Currently, breast cancer is clinically divided into 4 types: Luminal A type (ER+ / PR+, HER-2-), Luminal B type (ER+ / PR+, HER-2+), HER-2+ type (ER- / PR- / HER-2+) and triple-negative breast cancer (ER- / PR- / HER-2-). Among them, the current status of triple-negative breast cancer accounts for 15%-23.8% of all breast cancer pathological types. There are about 400,000 to 700,000 patie...

AI Technical Summary

Problems solved by technology

Since most of the cells in the tumor come from the human body itself, and some tumor cells also express molecules on the surface that prevent them from being recognized by the immune system (such as immune checkpoints), the immune response caused by most DC vaccines cannot successfully kill the tumor. Therapeutic effect is limited

[0012] 2. The target antigens of most DC vaccines are expressed not only on cancer cells but also on a few normal cells. The immune system has a certain probability of attacking normal cells

[0013] 3. The existing DC vaccines require DCs to present antigens to the immune system, and gradually initiate immunity. The effect is slow, and the treatment process is longer than other immunotherapies such as CAR-T.

[0014] 4. In addition, because many tumor cells can secrete a variety of cytokines that inhibit the maturation of dendritic cells in the body, the number of dendritic cells present in the tumor site is relatively small, and the expression of MHC molecules on the surface of dendritic cells is affected, weakening dendritic cells. The antigen presentation function of the cells leads to the inability of the anti-tumor immune response induced by dendritic cells to have a significant therapeutic effect in the host, and most of them can only achieve partial remission

[0015] 5. At present, there is still a lack of very effective reagents and drugs for breast cancer and liver cancer in clinical practice, and it is urgent to develop and find a new way to solve or partially solve the pain of breast cancer or liver cancer patients

Images